Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: Results from the German compassionate-use programme

European Urology

Volumn 63, Issue 6, 2013, Pages 977-982

  Heidenreich, Axel ^a   Scholz, Hans Jörg ^b   Rogenhofer, Sebastian ^c   Arsov, Christian ^d   Retz, Margitta ^e   Müller, Stefan C ^c   Albers, Peter ^d   Gschwend, Jürgen ^e   Wirth, Manfred ^f   Steiner, Ursula ^g   Miller, Kurt ^g   Heinrich, Elmar ^h   Trojan, Lutz ^h   Volkmer, Björn ⁱ   Honecker, Friedhelm ^j   Bokemeyer, Carsten ^j   Keck, Bastian ^k   Otremba, Burkhard ^l   Ecstein Fraisse, Evelyne ^m   Pfister, David ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Asklepios Klink GmbH Weissenfels   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF MANNHEIM   (Germany)

ⁱ KLINIKUM KASSEL   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l Onkologische Gemeinschaftspraxis   (Germany)

^m SANOFI   (France)

more..

Author keywords

Castration resistant prostate cancer; Chemotherapy; Docetaxel; Mitoxantrone

Indexed keywords

CABAZITAXEL; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPASSIONATE USE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FLANK PAIN; FOLLOW UP; HEART INFARCTION; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPASSIONATE USE TRIALS; DISEASE-FREE SURVIVAL; FEVER; GERMANY; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEUTROPENIA; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84876464927     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.058     Document Type: Article

References (16)

1. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
2. J.C. Eymard, S. Oudard, and G. Gravis Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study BJU Int 106 2010 974 978
3. O. Caffo, G. Pappagallo, and S. Brugnara Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors Urology 79 2012 644 649
4. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus Cbz or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
5. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
6. H.I. Scher, K. Fizazi, and F. Saad Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study [abstract LBA1] J Clin Oncol 30 Suppl 5 2012
7. C. Parker, D. Heinrich, and J.M. O'Sullivan Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract 8] J Clin Oncol 30 Suppl 5 2012
8. A.W. Aller, L.A. Kraus, and M.-C. Bissery In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract 1923] Proc Am Assoc Cancer Res 41 2000 303
9. M.-C. Bissery, H. Bouchard, and J.F. Riou Preclinical evaluation of TXD258, a new taxoid [abstract 1364] Proc Am Assoc Cancer Res 41 2000 214
10. B.P. Bouchet, and C.M. Galmarini Cabazitaxel, a new taxane with favorable properties Drugs Today (Barc) 46 2010 735 742
11. A.C. Mita, L.J. Denis, and E.K. Rowinsky Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
12. X. Pivot, P. Koralewski, and J.L. Hidalgo A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann Oncol 19 2008 1547 1552
13. S. Cisternino, F. Bourasset, Y. Archimbaud, D. Semiond, G. Sanderink, and J.M. Scherrmann Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats Br J Pharmacol 138 2003 1367 1375
14. T.J. Smith, J. Khatcheressian, and G.H. Lyman 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 2006 3187 3205
15. S.E. Bavbek, Z. Malik, and G. Di Lorenzo A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: interim results [abstract 172] J Clin Oncol 30 Suppl 5 2012
16. Bahl AK, Masson S, Malik Z, et al. Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): interim safety and quality of life (QOL) data from the UK early access programme. Presented at: European Association of Urology annual congress; February 24-28, 2012; Paris, France.